JP2019506408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506408A5 JP2019506408A5 JP2018539976A JP2018539976A JP2019506408A5 JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5 JP 2018539976 A JP2018539976 A JP 2018539976A JP 2018539976 A JP2018539976 A JP 2018539976A JP 2019506408 A5 JP2019506408 A5 JP 2019506408A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- subject
- agent
- appendix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662290202P | 2016-02-02 | 2016-02-02 | |
| US62/290,202 | 2016-02-02 | ||
| PCT/US2017/016120 WO2017136492A1 (en) | 2016-02-02 | 2017-02-02 | Use of cd24 proteins for treating leptin-deficient conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506408A JP2019506408A (ja) | 2019-03-07 |
| JP2019506408A5 true JP2019506408A5 (enExample) | 2020-03-12 |
| JP6938835B2 JP6938835B2 (ja) | 2021-09-22 |
Family
ID=59500202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539976A Expired - Fee Related JP6938835B2 (ja) | 2016-02-02 | 2017-02-02 | レプチン欠乏状態を治療するためのｃｄ２４タンパク質の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10799558B2 (enExample) |
| EP (1) | EP3411062B1 (enExample) |
| JP (1) | JP6938835B2 (enExample) |
| KR (1) | KR20180120145A (enExample) |
| CN (1) | CN109069583B (enExample) |
| CA (1) | CA3012466A1 (enExample) |
| SG (1) | SG11201806338SA (enExample) |
| WO (1) | WO2017136492A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630158B1 (en) * | 2017-05-22 | 2022-07-13 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |
| US20210046154A1 (en) * | 2018-03-05 | 2021-02-18 | Oncoimmune, Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| TW202015753A (zh) * | 2018-06-04 | 2020-05-01 | 美商昂科免疫公司 | 以cd24預防及治療移植物抗宿主病及黏膜炎之方法 |
| WO2020163529A1 (en) | 2019-02-06 | 2020-08-13 | Oncoimmune, Inc. | Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072325A1 (en) * | 2000-03-29 | 2001-10-04 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| JP2007504842A (ja) * | 2003-05-29 | 2007-03-08 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| CA2851602C (en) | 2011-08-30 | 2020-07-14 | Academisch Medisch Centrum | Method for preventing and/or treating insulin resistance |
| WO2014071379A1 (en) * | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Dosing and administration of oligonucleotide cancer therapies |
-
2017
- 2017-02-02 US US16/074,726 patent/US10799558B2/en not_active Expired - Fee Related
- 2017-02-02 CA CA3012466A patent/CA3012466A1/en not_active Abandoned
- 2017-02-02 WO PCT/US2017/016120 patent/WO2017136492A1/en not_active Ceased
- 2017-02-02 KR KR1020187022125A patent/KR20180120145A/ko not_active Ceased
- 2017-02-02 EP EP17748111.6A patent/EP3411062B1/en active Active
- 2017-02-02 SG SG11201806338SA patent/SG11201806338SA/en unknown
- 2017-02-02 CN CN201780008474.2A patent/CN109069583B/zh not_active Expired - Fee Related
- 2017-02-02 JP JP2018539976A patent/JP6938835B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-12 US US17/067,929 patent/US20210162006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP7725551B2 (ja) | アクチビンｉｉａ型受容体変異体を含む医薬組成物 | |
| AU2012252153B2 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| JP2025138661A (ja) | Ｆｃｒｎ抗体およびその使用の方法 | |
| JP2015500811A5 (enExample) | ||
| TW200908995A (en) | Antibody formulations | |
| AU2012205384B2 (en) | IL-27 antagonists for treating inflammatory diseases | |
| JP2019507589A5 (enExample) | ||
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| ES2655941T3 (es) | Proteína de fusión | |
| JP6562912B2 (ja) | Ｃｂ１受容体抗原結合タンパク質及びその使用 | |
| AU2017205343A1 (en) | Self-crosslinking antibodies | |
| EP4138998A2 (en) | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the ace2 receptor | |
| NO324206B1 (no) | Antistoffer mot interferon alfa-/beta-reseptorer og fremgangsmater for fremstilling og anvendelse derav, samt DNA-molekyl, ekspresjonsvektor, vertscelle, farmasoytisk sammensetning, hybridom og sett. | |
| WO2016019036A2 (en) | Recombinant collagen iv surrogates and uses thereof | |
| JP2011032188A (ja) | 融合蛋白質 | |
| TW202544038A (zh) | 用於治療甲狀腺眼病的方法 | |
| JP5137818B2 (ja) | 関節リウマチの処置剤 | |
| WO2000023477A9 (en) | Immunoglobulin variants | |
| IL301202A (en) | Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them | |
| US20230416378A1 (en) | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases | |
| JP2024540220A5 (enExample) | ||
| JP2003525040A (ja) | 治療用ペプチド | |
| WO2005058358B1 (en) | Use of agents derived from ceacam1 for the treatment of inflammatory diseases | |
| CN116333145B (zh) | 结合活化凝血因子ix的抗体 |